



## **Non-Confidential Technology Disclosure**

**Title:** Disease Markers for Early Stage Atherosclerosis

**Inventors:** Charles Kiefer, Ph.D., Michael Snyder, M.D., James McKenney, M.H.A., Jane Trainor, Department of Hospital Laboratories, University of Massachusetts Medical School and UMass Memorial Medical Center, Inc.

**Description:** This invention provides markers which may be used to diagnose a person with early stage atherosclerosis. During the pre-atherosclerosis stage, there is an accumulation of neutral lipid in the arterial matrix that is associated with degenerating elastin fibers. During this stage, where a patient is primarily asymptomatic, the disease is most reversible. Therefore, if the disease could be detected at this early stage, atherosclerosis could be treated preventively.

**Application:** This technology may be used to predict the onset of atherosclerosis at an early stage and thus provide a better chance for treatment. It may be used for adults, adolescents, children, and patients with risk factors for development of atherosclerosis.

**Advantage:** This technology is advantageous as:

- The markers are diagnostic of the earliest preclinical stages of atherosclerosis development.
- Early disease identification allows earlier, more mild treatment and possible prevention of full-blown atherosclerosis.
- It can be used to identify patients developing atherosclerosis before becoming symptomatic.
- The markers could be used to assess efficacy of treatment.

**Patent Status:** Patent pending

**Licensing Status:** Available to license

**Docket:** UMMC 04-82

**Contact:** Anita L. Ballesteros, Ph.D.  
Licensing Officer  
Phone: (508) 856-6611  
[Anita.ballesteros@umassmed.edu](mailto:Anita.ballesteros@umassmed.edu)